Investigators tested a new neoadjuvant immunotherapy to fight prostate cancer using a virus-mimicking drug to activate the immune system.

An individual-patient meta-analysis sheds light on the optimal duration of androgen deprivation therapy in men with prostate cancer on definitive radiotherapy.

Prostate cancer (PCa) remains a significant global health challenge, with rising morbidity rates and poor prognosis associated with advanced stages ...

PRESS RELEASEAB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR UNITED STATES PATENT COVERING MASITINIB IN THE TREATMENT OF METASTATIC CASTRATE ...

Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, ...

Florida Cancer Specialists & Research Institute, LLC (FCS) is among the first oncology providers in Florida selected to ...

Understanding how a normal healthy cell turns into a cancerous one is our best bet yet for beating the disease. It will help better diagnose the cancer type, and enable the development of more ...

Men with relatively unaggressive prostate tumors and whose disease is carefully monitored by urologists are unlikely to develop metastatic prostate cancer or die of their cancers, according to results ...